困惑领域：贝特类药物治疗心血管疾病的未来前景 - Suppr

Suppr

超能文献

Field of confusion: future prospects for fibrate therapy in cardiovascular disease.

作者信息

Rosenson Robert S

出版信息

Curr Atheroscler Rep. 2006 May;8(3):219-22. doi: 10.1007/s11883-006-0076-y.

DOI:10.1007/s11883-006-0076-y

PMID:16640958

Abstract

摘要

相似文献

Field of confusion: future prospects for fibrate therapy in cardiovascular disease.困惑领域：贝特类药物治疗心血管疾病的未来前景

Curr Atheroscler Rep. 2006 May;8(3):219-22. doi: 10.1007/s11883-006-0076-y.

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.长期非诺贝特治疗对9795例2型糖尿病患者心血管事件的影响（FIELD研究）：随机对照试验

Lancet. 2005 Nov 26;366(9500):1849-61. doi: 10.1016/S0140-6736(05)67667-2.

Combination lipid therapy in type 2 diabetes.2型糖尿病的联合降脂治疗。

N Engl J Med. 2010 Aug 12;363(7):692-4; author reply 694-5. doi: 10.1056/NEJMc1006407.

Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.非诺贝特治疗与他汀类药物治疗的 2 型糖尿病患者的长期心血管风险的关联。

JAMA Cardiol. 2017 Apr 1;2(4):370-380. doi: 10.1001/jamacardio.2016.4828.

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].非诺贝特干预与糖尿病事件降低（FIELD）研究：非诺贝特的基线特征和短期效应[国际标准随机对照试验编号64783481]

Cardiovasc Diabetol. 2005 Aug 22;4:13. doi: 10.1186/1475-2840-4-13.

[HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].[罗格列酮和非诺贝特治疗2型糖尿病血脂异常患者期间高密度脂蛋白胆固醇的降低情况]

Korean J Lab Med. 2010 Feb;30(1):17-9. doi: 10.3343/kjlm.2010.30.1.17.

Fibrates consistently lower risk of cardiovascular events across high-risk groups.贝特类药物持续降低高危人群发生心血管事件的风险。

Cardiovasc J Afr. 2010 May-Jun;21(3):174.

More clinical lessons from the FIELD study.FIELD研究带来的更多临床启示。

Cardiovasc Drugs Ther. 2009 Jun;23(3):235-41. doi: 10.1007/s10557-008-6160-5.

Fibrates: where are we now?贝特类药物：我们如今处于什么阶段？

Ther Adv Cardiovasc Dis. 2009 Feb;3(1):91-6. doi: 10.1177/1753944708096281.

Differential associations of statin and fibrate treatment with carotid arterial remodeling.他汀类药物和贝特类药物治疗与颈动脉重塑的差异关联。

Am J Hypertens. 2005 Nov;18(11):1476-81. doi: 10.1016/j.amjhyper.2005.05.019.

引用本文的文献

Macrophage angiotensin-converting enzyme reduces atherosclerosis by increasing peroxisome proliferator-activated receptor α and fundamentally changing lipid metabolism.巨噬细胞血管紧张素转换酶通过增加过氧化物酶体增殖物激活受体α并从根本上改变脂质代谢来减少动脉粥样硬化。

Cardiovasc Res. 2023 Aug 7;119(9):1825-1841. doi: 10.1093/cvr/cvad082.

Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects.调节过氧化物酶体增殖物激活受体以获得治疗益处？生物学、临床经验和未来前景。

Am Heart J. 2012 Nov;164(5):672-80. doi: 10.1016/j.ahj.2012.06.023. Epub 2012 Oct 16.

Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction.联合治疗用于动脉粥样硬化的治疗或预防：重点关注脂质-肾素-血管紧张素系统的相互作用。

Atherosclerosis. 2010 Apr;209(2):307-13. doi: 10.1016/j.atherosclerosis.2009.09.007. Epub 2009 Sep 12.

Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.混合性高脂血症治疗的血管及代谢效应：聚焦他汀类药物与贝特类药物

Int J Cardiol. 2008 Feb 29;124(2):149-59. doi: 10.1016/j.ijcard.2007.04.080. Epub 2007 Jul 20.

本文引用的文献

Lancet. 2005 Nov 26;366(9500):1849-61. doi: 10.1016/S0140-6736(05)67667-2.

New approaches in the intensive management of cardiovascular risk in the metabolic syndrome.代谢综合征心血管风险强化管理的新方法。

Curr Probl Cardiol. 2005 May;30(5):241-79. doi: 10.1016/j.cpcardiol.2004.10.001.

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.阿托伐他汀在2型糖尿病中对心血管疾病的一级预防：合作阿托伐他汀糖尿病研究（CARDS）：多中心随机安慰剂对照试验

Lancet. 2004;364(9435):685-96. doi: 10.1016/S0140-6736(04)16895-5.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.近期临床试验对美国国家胆固醇教育计划成人治疗组第三次指南的影响。

Circulation. 2004 Jul 13;110(2):227-39. doi: 10.1161/01.CIR.0000133317.49796.0E.

Current overview of statin-induced myopathy.他汀类药物所致肌病的当前概述。

Am J Med. 2004 Mar 15;116(6):408-16. doi: 10.1016/j.amjmed.2003.10.033.

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.欧洲临床实践中心血管疾病预防指南。欧洲及其他学会心血管疾病预防临床实践联合工作组第三次报告

Eur Heart J. 2003 Sep;24(17):1601-10. doi: 10.1016/s0195-668x(03)00347-6.

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.MRC/BHF糖尿病患者使用辛伐他汀降低胆固醇的心脏保护研究：一项随机安慰剂对照试验（涉及5963名糖尿病患者）

Lancet. 2003 Jun 14;361(9374):2005-16. doi: 10.1016/s0140-6736(03)13636-7.

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.在盎格鲁-斯堪的纳维亚心脏结局试验——降脂分支（ASCOT-LLA）中，阿托伐他汀对胆固醇浓度处于平均水平或低于平均水平的高血压患者冠心病和中风事件的预防作用：一项多中心随机对照试验。

Lancet. 2003 Apr 5;361(9364):1149-58. doi: 10.1016/S0140-6736(03)12948-0.

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).糖尿病、血浆胰岛素与心血管疾病：来自退伍军人事务部高密度脂蛋白干预试验（VA-HIT）的亚组分析

Arch Intern Med. 2002;162(22):2597-604. doi: 10.1001/archinte.162.22.2597.

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).国家胆固醇教育计划（NCEP）成人高血胆固醇检测、评估与治疗专家小组第三次报告（成人治疗小组第三次报告）执行摘要

JAMA. 2001 May 16;285(19):2486-97. doi: 10.1001/jama.285.19.2486.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验